The way forward for Ketamine and Mood Disorders In 2019, the FDA and European Commission authorized the usage of an esketamine nasal spready under the brand identify Spravato to deal with melancholy. Even so, as of 2021, ketamine hasn't been accredited through the FDA to treat depression or other psychological health disorders, and for that reason,